FDA advisory committee to review Collegium’s Xtampza ER for chronic pain
Xtampza ER, Collegium’s lead product candidate, is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is being developed for the management of pain severe enough to require